222 related articles for article (PubMed ID: 24924184)
1. Natural killer cells for osteosarcoma.
Tarek N; Lee DA
Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cell Immunotherapy for Osteosarcoma.
Tullius BP; Setty BA; Lee DA
Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
[TBL] [Abstract][Full Text] [Related]
3. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
4. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.
Guma SR; Lee DA; Yu L; Gordon N; Hughes D; Stewart J; Wang WL; Kleinerman ES
Pediatr Blood Cancer; 2014 Apr; 61(4):618-26. PubMed ID: 24136885
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
Kubista B; Trieb K; Blahovec H; Kotz R; Micksche M
Anticancer Res; 2002; 22(2A):789-92. PubMed ID: 12014651
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target.
Zhu Y; Huang B; Shi J
Oncotarget; 2016 Jul; 7(30):47163-47172. PubMed ID: 27323411
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytolytic activity of human NK cells against osteosarcoma cell lines.
Tarozzi A; Mariani E; Facchini A
Boll Soc Ital Biol Sper; 1995; 71(7-8):221-6. PubMed ID: 8519499
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
11. Leveraging natural killer cells for cancer immunotherapy.
Grossenbacher SK; Aguilar EG; Murphy WJ
Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.
Luksch R; Perotti D; Cefalo G; Gambacorti Passerini C; Massimino M; Spreafico F; Casanova M; Ferrari A; Terenziani M; Polastri D; Gambirasio F; Podda M; Bozzi F; Ravagnani F; Parmiani G; Fossati Bellani F
Tumori; 2003; 89(3):263-8. PubMed ID: 12908780
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
Buddingh EP; Schilham MW; Ruslan SE; Berghuis D; Szuhai K; Suurmond J; Taminiau AH; Gelderblom H; Egeler RM; Serra M; Hogendoorn PC; Lankester AC
Cancer Immunol Immunother; 2011 Apr; 60(4):575-86. PubMed ID: 21240486
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
15. The biology of natural killer cells and implications for therapy of human disease.
Chiorean EG; Miller JS
J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
17. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma.
Zhang ML; Chen L; Li YJ; Kong DL
Oncol Rep; 2019 Nov; 42(5):2049-2056. PubMed ID: 31485666
[TBL] [Abstract][Full Text] [Related]
18. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.
Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D
J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified T-cell therapy for osteosarcoma.
DeRenzo C; Gottschalk S
Adv Exp Med Biol; 2014; 804():323-40. PubMed ID: 24924183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]